THE USE OF 1E12, A MONOCLONAL ANTI-PLATELET FACTOR 4 ANTIBODY TO IMPROVE THE DIAGNOSIS OF VACCINE-INDUCED IMMUNE THROMBOTIC THROMBOCYTOPENIA
JOURNAL OF THROMBOSIS AND HAEMOSTASIS(2024)
摘要
Background: Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a complication of adenoviral-based vaccine against SARS-CoV-2 due to pro- thrombotic immunoglobulin (Ig) G antibodies to platelet factor 4 (PF4) and may be difficult to distinguish from heparin-induced thrombocytopenia (HIT) in patients treated with heparin. Objectives: We assessed the usefulness of competitive anti-PF4 enzyme immunoassays (EIAs) in this context. Methods: The ability of F(ab ')2 ' )2 fragments of 1E12, 1C12, and 2E1, 3 monoclonal antiPF4 antibodies, to inhibit the binding of human VITT or HIT antibodies to PF4 was evaluated using EIAs. Alanine-scanning mutagenesis was performed to define the amino acids involved in the interactions between the monoclonal antibodies and PF4. Results: A strong inhibition of VITT IgG binding to PF4 was measured with 1E12 (median inhibition, 93%; n = 8), whereas it had no effect on the binding of HIT antibodies (median, 6%; n = 8). In contrast, 1C12 and 2E1 inhibited VITT (median, 74% and 76%, respectively) and HIT antibodies (median, 68% and 53%, respectively) binding to PF4. When a competitive anti-PF4 EIA was performed with 1E12 for 19 additional VITT samples, it strongly inhibited IgG binding to PF4, except for 1 patient, who had actually developed HIT according to the clinical history. Epitope mapping showed that 1E12 interacts with 5 key amino acids on PF4, of which 4 are also required for the binding of human VITT antibodies, thus explaining the competitive inhibition. Conclusion: A simple competitive anti-PF4 EIA with 1E12 could help confirm VITT diagnosis and distinguish it from HIT in patients when both diagnoses are possible.
更多查看译文
关键词
immunoassay,platelet factor 4,thrombocytopenia,thrombosis,vaccines
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要